Before initiating radiotherapeutic clinical trials for these inhibitors in radioresistant CRCs, the testing of ATM inhibitors in relevant CRC mouse models should be performed to confirm their potential effectiveness as sensitizers of radioresistant tumor cells in vivo, similar to studies in mouse models for melanoma and glioblastoma [44,68]. This evidence concerns the gene ATM and melanoma.